nature portfolio

Corresponding author(s):	Manuel Teichert
Last updated by author(s):	Feb 26, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

~ .			
St	at	isti	CS

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
	\boxtimes	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	$ \times $	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	\boxtimes	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\times		A description of all covariates tested
	$ \times $	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	\boxtimes	Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about <u>availability of computer code</u>

Data collection

Intrinsic imaging: Kalatsky system. Electropysiology in vivo: Clampex 10.4. Serial 2-Photon: Scan Image (v5.6). Whisker reconstruction: CloudCompare v.2.12. Optophysiology: Matlab 2019 (MathWorks)

Data analysis

Kalatsky system, Matlab 2019-2023 (MathWorks), Python 3.9, Blender 3.2.0, GraphPad Prism 9

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The data supporting the findings of this study are stored in the Source Data file. Costum codes are stored here: https://github.com/simonweiler/cross_modal_SSp_VISp; Data are available under the following link: https://figshare.com/articles/preprint/A_primary_sensory_cortical_interareal_feedfo[...]atlab_Data_structure_for_slice_electrophysiology_data/22090580

Research	involving	human	participants,	their data,	or biological	material

and sexual orientatio		thnicity and racism.
Reporting on sex ar	nd gender	N/A
Reporting on race, other socially releva		N/A
Population characte	eristics	N/A
Recruitment		N/A
Ethics oversight		N/A
Note that full information	on on the appro	oval of the study protocol must also be provided in the manuscript.
Field-spec	cific re	porting
<u> </u>		s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences	В	ehavioural & social sciences
For a reference copy of the	e document with a	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
Life sciend	ces stu	udy design
All studies must disclo	ose on these	points even when the disclosure is negative.
'	3Dihub; https://	ious studies in the lab and in the research field. https://www.sciencedirect.com/science/article/pii/S1053811917306055?via%/www.nature.com/articles/nprot.2018.026; https://journals.biologists.com/jeb/article/226/19/jeb245597/333454/orphology-of-the-whiskers-and-faces
		agical experiments neurons with a high series resistance (>30 MOhm) were excluded. Animals with insufficient expression of were excluded. Otherwise no data exclusion.
		replicated across several mice of both sexes. The number of replications (number of mice) are listed in all figure legends and ne animals (sex, age) are provided in the source data file and the Methods.
Randomization A	Animal sex, allo	ecation to experimental groups and all stimuli applied (visual, whisker, optogenetics) were randomized.
Blinding	3linding was no	ot possible given that experiments including two groups were performed by a single experimentor.
		ocial sciences study design
		points even when the disclosure is negative.
Study description	N/A	
Research sample	N/A	
Sampling strategy	N/A	
Data collection	N/A	
Timing	N/A	
Data exclusions	N/A	
Non-participation	N/A	
Randomization	N/A	

Ecological, e	volutionary & environmental sciences study design
	these points even when the disclosure is negative.
Study description	N/A
Research sample	N/A
Sampling strategy	N/A
Data collection	N/A
Timing and spatial scale	N/A
Data exclusions	N/A
Reproducibility	N/A
Randomization	N/A
Blinding	N/A
Did the study involve field	d work?
Field conditions	N/A
Location	N/A
Access & import/export	N/A
Disturbance	N/A
We require information from a	r specific materials, systems and methods authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, evant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. Methods
Antibodies	ChIP-seq
Eukaryotic cell lines Palaeontology and a	Flow cytometry MRI-based neuroimaging
Palaeontology and a	
Clinical data	
Dual use research o	f concern

Antibodies

	rabbit-anti-c-fos, 1:250, Santa Cruz (sc-8047); rabbit-anti-PV, 1:1000, Abcam (directly labeled to Alexa 488 by a Zenon Rabbit-antio IgG labeling Kit); goat-anti-SOM, 1:100, Santa cruz; Alexa488 donkey-anti-rabbit, 1:1000, Cy3 goat-anti-rabbit, 1:1000, Jackson Immuno Research
Validation	https://pubmed.ncbi.nlm.nih.gov/28735013/

Eukaryotic cell lin	es	
Policy information about <u>ce</u>	ell lines	and Sex and Gender in Research
Cell line source(s)		N/A
Authentication		N/A
Mycoplasma contaminati	on	N/A
Commonly misidentified (See <u>ICLAC</u> register)	lines	N/A
Palaeontology an	d Arc	chaeology
Specimen provenance	N/A	
Specimen deposition	N/A	
Dating methods	N/A	
Tick this box to confirm	m that	the raw and calibrated dates are available in the paper or in Supplementary Information.
Ethics oversight	N/A	
		oval of the study protocol must also be provided in the manuscript.
Animals and othe		
Policy information about <u>st</u> Research	<u>udies ir</u>	nvolving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in
Laboratory animals		e, C57BL6, Ai14 (Cre-dependent tdTomato reporter), Ntsr1-Cre-tdTomato, GAD2-cre-tdTomato, PV-cre tdTomato (all C57BL6 ound); Age: 4-14 weeks, Sex: both
Wild animals	No wild	d animals were used in this study.
Reporting on sex	both se	exes
Field-collected samples	No field	d-collected samples were used in this study.
Ethics oversight		l Welfare and Ethical Review Body (AWERB; Sainsbury Wellcome Centre for Neural Circuits and Behaviour), Thüringer samt für Verbraucherschutz (Bad Langensalza, Germany)
Note that full information on the		oval of the study protocol must also be provided in the manuscript.
Clinical data		
Policy information about <u>cli</u> All manuscripts should comply		tudies e ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration	N/A	
Study protocol	N/A	
Data collection	N/A	

Dual use research of concern

Policy information about <u>dual use research of concern</u>

N/A

Hazards

Outcomes

Could the accidental, deli in the manuscript, pose a		or reckless misuse of agents or technologies generated in the work, or the application of information presented to:
No Yes		
Public health		
National security		
Crops and/or livest	ock:	
Ecosystems		
Any other significa	nt area	
Experiments of concer	n	
Does the work involve an	y of the	ese experiments of concern:
No Yes		
Demonstrate how	to rende	er a vaccine ineffective
	o thera	peutically useful antibiotics or antiviral agents
	nce of a	pathogen or render a nonpathogen virulent
Increase transmissi		
Alter the host rang		
		ic/detection modalities
		of a biological agent or toxin
Any other potentia	illy harm	oful combination of experiments and agents
Plants		
Tidites		
Seed stocks	N/A	
Novel plant genotypes	N/A	
Authentication	N/A	
Cl ID		
ChIP-seq		
Data deposition		
Confirm that both raw	v and fi	nal processed data have been deposited in a public database such as <u>GEO</u> .
Confirm that you have	e depos	sited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links May remain private before public	cation.	N/A
Files in database submissi	ion	N/A
Genome browser session (e.g. <u>UCSC</u>)		N/A
Methodology		
Replicates	N/A	
Sequencing depth	N/A	
Antibodies	N/A	
Peak calling parameters	N/A	

Data quality	N/A	
Software	N/A	
Flow Cytometry		
Plots		
Confirm that:	ne marker a	and fluorochrome used (e.g. CD4-FITC).
		Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
		utliers or pseudocolor plots.
A numerical value for	number of	cells or percentage (with statistics) is provided.
Methodology		
Sample preparation	N/A	
Instrument	N/A	
Software	N/A	
Cell population abundance	ce N/A	
Gating strategy	N/A	
Tick this box to confirm	m that a fig	ure exemplifying the gating strategy is provided in the Supplementary Information.
Magnetic recens	oco ima	ging
Magnetic resonar	тсе ппа	<u>giiig</u>
Experimental design		
Design type		N/A
Design specifications		N/A
Behavioral performance r	measures	N/A
Acquisition		
Imaging type(s)		N/A
Field strength		N/A
Sequence & imaging para	meters	N/A
Area of acquisition		N/A
Diffusion MRI	Used	☐ Not used
Preprocessing		
Preprocessing software	N/A	
Normalization	N/A	
Normalization template	N/A	
Noise and artifact remova	al N/A	
Volume censoring	N/A	
Statistical modeling &	inference	
Model type and settings	N/A	

nature
re portfolio
ō
reporting summary

<u> </u>		
April 2(
) 	٧.	
) 	۳	۰
<u> </u>	S	
$\frac{1}{2}$		
\geq		٤
~~		
$\overline{}$		
	K	í